- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05754528
Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)
August 3, 2023 updated by: Ottawa Hospital Research Institute
A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)
The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance.
Participants will be randomized to standard daily dosing of endocrine therapy or endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Breast cancer remains the most common cancer diagnosis and second leading cause of cancer death among Canadian women.
Close to 70% of breast cancers are hormone-dependent and endocrine therapy is the mainstay treatment (such as tamoxifen, aromatase inhibitors and lutenizing hormone-releasing hormone analogs).
Globally, endocrine therapy has led to the greatest benefit for breast cancer patients resulting in compelling reductions in breast cancer recurrence and mortality rates.
Tamoxifen and aromatase inhibitors (e.g.
letrozole, anastrozole and exemestane) can cause a variable degree of toxicity linked to estrogen deprivation such as: vasomotor symptoms (hot flashes and night sweats), arthralgia/joint stiffness, genitourinary symptoms (vaginal dryness, dysuria, urinary incontinence, recurrent urinary tract infections and pain during sexual intercourse), insomnia, weight gain, mood changes, cognitive dysfunction, fatigue and skin dryness.
It is well acknowledged that endocrine therapy side effects can influence treatment adherence, compliance, and persistence.
A systematic review of adjuvant endocrine treatment found that 41 to 72% of patients did not take the correct dosage at the prescribed frequency and 31 to 73% discontinued endocrine therapy.
Treatment adherence and persistence are key issues in breast cancer, as early cessation or reduced compliance/adherence to hormonal therapy leads to reduced disease-free survival and increased mortality.
Despite a plethora of studies aimed at reducing the side effects of endocrine therapy there is no clear evidence that any of them have resulted in improved adherence/compliance/persistence.
In practice, it is common to see a clinician reducing dose-intensity or frequency when patients develop intolerable side effects from endocrine therapy, i.e. either using 10 mg instead of 20 mg of Tamoxifen daily, or an every other day schedule for aromatase inhibitors.
However, this commonly used practice has not been evaluated in a prospective trial.
The researchers propose to conduct the world's first prospective randomized clinical trial to evaluate a dose-frequency escalation strategy of endocrine therapy (meaning taking the dose every other day for 1 month and then daily) and its effects on adherence and tolerability.
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Vandermeer, MSc
- Phone Number: 70170 613-737-7700
- Email: lvandermeer@ohri.ca
Study Contact Backup
- Name: Deanna Saunders
- Phone Number: 79425 613-737-7700
- Email: dsaunders@ohri.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada
- Recruiting
- The Ottawa Hospital Cancer Centre
-
Contact:
- Lisa Vandermeer, MSc
- Phone Number: 70297 6136377700
- Email: lvandermeer@ohri.ca
-
Principal Investigator:
- Marie-France Savard, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with an early stage or locally advanced hormonal receptor positive breast cancer
- Plan to receive endocrine therapy
- Able to provide oral consent
- Willing and able to complete questionnaires as per study protocol
Exclusion Criteria:
- Metastatic cancer
- Adjuvant abemaciclib
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard daily dosing of endocrine therapy
|
Standard daily dosing of endocrine therapy.
Defined as taking endocrine therapy every day from the start.
|
Experimental: Endocrine therapy dose-frequency escalation
Endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
|
Endocrine therapy dose-frequency escalation.
Defined as taking endocrine therapy every other day for 1 month and then daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year adherence with prescribed endocrine therapy
Time Frame: 1 year after start of endocrine therapy
|
1-year adherence with prescribed endocrine therapy measured by the validated Five-item Medication Adherence Report Scale (MARS-5 score).
The MARS-5 score can range from 5 to 25 indicating greater level of adherence.
A participant will be considered adherent if they have a MARS-5 score of 23 and more (specificity and sensitivity maximized at this value).
The adherence rate at 1-year will be calculated as the number of patients who are initially enrolled in the study.
Participants who do not complete the 1-year MARS-5 questionnaire will be considered as non-adherent for the primary analysis of adherence rate.
|
1 year after start of endocrine therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence rates with prescribed endocrine therapy
Time Frame: Through study completion, 5 years
|
adherence with prescribed endocrine therapy measured by the validated Five-item Medication Adherence Report Scale (MARS-5 score).
The MARS-5 score can range from 5 to 25 indicating greater level of adherence.
A participant will be considered adherent if they have a MARS-5 score of 23 and more (specificity and sensitivity maximized at this value).
|
Through study completion, 5 years
|
Persistence with prescribed endocrine therapy
Time Frame: Through study completion, 5 years
|
Rates of persistence with prescribed endocrine therapy measured by a non-validated endocrine therapy adherence questionnaire.
|
Through study completion, 5 years
|
Endocrine toxicity and tolerability
Time Frame: Through study completion, 5 years
|
Endocrine toxicity and tolerability measured by the change in total score and individual items of the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) score, a validated subscale of the FACIT measurement system from baseline to 6 months, 1 year and 5 years following the beginning of endocrine therapy.
The FACT-ES is a 46 item, 5 point Likert-type scale questionnaire that asks questions relating to physical well-being, social/family well-being, emotional well-being, functional well-being and the endocrine symptom subscale.
|
Through study completion, 5 years
|
Patient health-related quality of life
Time Frame: Through study completion, 5 years
|
Patient Health-Related Quality of Life (HR-QoL) measured by the change in the total score and individual subscales of the validated Functional Assessment of Cancer Therapy for patients with a Breast cancer (FACT-B) questionnaire from baseline to 6 months, 1 year and 5 years following the beginning of endocrine therapy.
The FACT-B is a 37 item, 5 point Likert-type scale questionnaire that asks questions relating to physical well-being, social/family well-being, emotional well-being, functional well-being and the breast cancer subscale.
|
Through study completion, 5 years
|
Endocrine therapy interruptions
Time Frame: Through study completion, 5 years
|
Endocrine therapy interruption periods will be collected throughout study.
An interruption is being defined as a pause in treatment for more than 7 days in a row.
|
Through study completion, 5 years
|
Endocrine therapy discontinuations
Time Frame: Through study completion, 5 years
|
Endocrine therapy discontinuation rates will be collected throughout study.
Discontinuation means stopping of endocrine therapy and not continuing, even on a different type.
|
Through study completion, 5 years
|
Endocrine therapy changes
Time Frame: Through study completion, 5 years
|
Alterations made to endocrine therapy for toxicity.
Meaning was there a change with the type of endocrine therapy used.
|
Through study completion, 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Marie-France Savard, MD, Ottawa Hospital Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2023
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2029
Study Registration Dates
First Submitted
February 8, 2023
First Submitted That Met QC Criteria
February 22, 2023
First Posted (Actual)
March 6, 2023
Study Record Updates
Last Update Posted (Actual)
August 7, 2023
Last Update Submitted That Met QC Criteria
August 3, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- REaCT-TEMPO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on Standard of care administration of Endocrine therapy
-
Ottawa Hospital Research InstituteCompleted
-
Roswell Park Cancer InstituteTerminated
-
University of California, San FranciscoMount Zion Health FundCompletedBreast Carcinoma | Colorectal CarcinomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedMelanoma | Health Status Unknown | Dysplastic Nevus | No Evidence of DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedAcute Leukemia | Refractory Leukemia | Recurrent LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid NeoplasmUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Medical Research Foundation, Oregon; ATS... and other collaboratorsActive, not recruitingLung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8United States